Medicinal chemistry of drugs used in diabetic cardiomyopathy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current Medicinal Chemistry

• Publication date

  2010-01-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/092986710790416281PMID 20015035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carvedilol

  2012cited by this paper
• Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model – the Zucker diabetic rat

  2009cited by this paper
• Development of Newer Calcium Channel Antagonists

  2009cited by this paper
• Endothelin-1-stimulated InsP3-induced Ca2+ release is a nexus for hypertrophic signaling in cardiac myocytes.

  2009cited by this paper
• Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study.

  2009cited by this paper
• Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: a pilot study.

  2009cited by this paper
• Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

  2009cited by this paper
• The Metallothionein/Thionein System: An Oxidoreductive Metabolic Zinc Link

  2009cited by this paper
• Effects of Efonidipine Hydrochloride on Heart Rate and Circulatory Changes Due to Stress

  2009cited by this paper
• The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems.

  2009cited by this paper
• Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL‐profiles

  2009cited by this paper
• In Half of Hypertensive Diabetics, Co-Administration of a Calcium Channel Blocker and an Angiotensin-Converting Enzyme Inhibitor Achieved a Target Blood Pressure of <130/80 mmHg: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes (ATTEST) Study

  2008cited by this paper
• The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.

  2008cited by this paper
• Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.

  2008cited by this paper
• Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy

  2008cited by this paper
• Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

  2008cited by this paper
• Metallothionein reverses the harmful effects of angiotensin II on the diabetic heart.

  2008cited by this paper
• Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

  2008cited by this paper
• Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase–Dependent Regulation of the Orphan Nuclear Receptor SHP

  2008cited by this paper
• The Effect of Trandolapril and Its Fixed-Dose Combination with Verapamil on Circulating Adhesion Molecules Levels in Hypertensive Patients with Type 2 Diabetes

  2008cited by this paper
• Intracellular Angiotensin II Production in Diabetic Rats Is Correlated With Cardiomyocyte Apoptosis, Oxidative Stress, and Cardiac Fibrosis

  2008cited by this paper
• Endothelin-1 and hypertension: From bench to bedside

  2008cited by this paper
• Akt activation prevents Apop-1-induced death of cells.

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.

  2008cited by this paper
• Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

  2008cited by this paper
• The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

  2008cited by this paper
• Ameliorative effect of Captopril and Valsartan on an animal model of diabetic cardiomyopathy.

  2008cited by this paper
• IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction.

  2008cited by this paper
• A review of evidence-based beta-blockers in special populations with heart failure.

  2008cited by this paper
• DPP4 Inhibitors: a new approach in diabetes treatment

  2008cited by this paper
• Is α‐lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity

  2008cited by this paper
• Sitagliptin

  2007cited by this paper
• Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction

  2007cited by this paper
• A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

  2007cited by this paper
• Moexipril and left ventricular hypertrophy

  2007cited by this paper
• Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade.

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Different redox states of metallothionein/thionein in biological tissue.

  2007cited by this paper
• Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.

  2007cited by this paper
• Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control

  2007cited by this paper
• Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy)

  2007cited by this paper
• Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

  2007cited by this paper
• Cilnidipine Improves Left-Ventricular Midwall Function Independently of Blood Pressure Changes in Chinese Patients With Hypertension

  2007cited by this paper
• Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS.

  2007cited by this paper
• Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)

  2007cited by this paper
• Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione.

  2007cited by this paper
• Role of endothelin‐1, sodium hydrogen exchanger‐1 and mitogen activated protein kinase (MAPK) activation in glucose‐induced cardiomyocyte hypertrophy

  2007cited by this paper
• Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats

  2007cited by this paper
• Candesartan cilexetil – a review of effects on cardiovascular complications in hypertension and chronic heart failure

  2007cited by this paper
• Acute effect of esmolol intravenously on coronary microcirculation in patients with idiopathic dilated cardiomyopathy.

  2007cited by this paper
• Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy

  2007cited by this paper
• Diabetes and metallothionein.

  2007cited by this paper
• The therapeutic potential of statins in neurological disorders.

  2007cited by this paper
• Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade.

  2007cited by this paper
• Defining the Role of Zofenopril in the Management of Hypertension and Ischemic Heart Disorders

  2007cited by this paper
• Protective action of amlodipine on cardiac negative inotropism induced by lipopolysaccharide in rats.

  2007cited by this paper
• Changes in expression of adrenomedullin in the myocardium of streptozotocin-induced diabetic rats.

  2007cited by this paper
• Chronic endothelin‐A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats

  2007cited by this paper
• A Review of Perindopril in the Reduction of Cardiovascular Events

  2006cited by this paper
• Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.

  2006cited by this paper
• Comparative Effects of Pranidipine with Amlodipine in Rats with Heart Failure

  2006cited by this paper
• Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy.

  2006cited by this paper
• Role of p90 Ribosomal S6 Kinase–Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium

  2006cited by this paper
• Diabetic cardiomyopathy: the search for a unifying hypothesis.

  2006cited by this paper
• The Role of Zofenopril in Myocardial Protection During Cardioplegia Arrest: An Isolated Rat Heart Model

  2006cited by this paper
• Oxidative stress and cardiovascular disease: antioxidants and unresolved issues.

  2006cited by this paper
• Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.

  2006cited by this paper
• An Update on the Etiology and Epidemiology of Diabetes Mellitus

  2006cited by this paper
• Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy.

  2006cited by this paper
• Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

  2005cited by this paper
• Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction

  2005cited by this paper
• Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?

  2005cited by this paper
• Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy.

  2005cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Differential Regulation of Angiotensin II-induced Expression of Connective Tissue Growth Factor by Protein Kinase C Isoforms in the Myocardium*

  2005cited by this paper
• Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

  2005cited by this paper
• Nateglinide – current and future role in the treatment of patients with type 2 diabetes mellitus

  2005cited by this paper
• Critical Differences Among Beta‐Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET

  2005cited by this paper
• The anti‐diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog

  2005cited by this paper
• Effect of Powdered Fermented Milk with Lactobacillus helveticus on Subjects with High-Normal Blood Pressure or Mild Hypertension

  2005cited by this paper
• Bosentan, the mixed ETA–ETB endothelin receptor antagonist, attenuated oxidative stress after experimental myocardial ischemia and reperfusion

  2005cited by this paper
• Antioxidant and Cardioprotective Properties of the Sulphydryl Angiotensinconverting Enzyme Inhibitor Zofenopril

  2005cited by this paper
• The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).

  2005cited by this paper
• Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes.

  2004cited by this paper
• Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.

  2004cited by this paper
• Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

  2004cited by this paper
• Renin–angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes

  2004cited by this paper
• Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease

  2004cited by this paper
• The Calcium Channel Antagonist Benidipine Reduces Plasma and Cardiac Endothelin-1 Levels in Type II Diabetic Rat Model

  2004cited by this paper
• Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: A short review

  2004cited by this paper
• Diabetic cardiomyopathy: mechanisms, diagnosis and treatment.

  2004cited by this paper
• Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val‐HeFT

  2004cited by this paper
• Effects on reperfusion injury of adding diltiazem to tepid blood cardioplegia.

  2004cited by this paper
• Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart

  2004cited by this paper
• Hypotensive peptides from milk proteins.

  2004cited by this paper
• Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure.

  2004cited by this paper
• Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats.

  2004cited by this paper
• Comparative Effects of Quinapril with Enalapril in Rats with Heart Failure

  2004cited by this paper
• The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).

  2004cited by this paper

• Camel Whey protein ameliorates type Ⅰ diabetic cardiomyopathy by mitigating oxidative stress, inflammation and apoptosis

  2026cites this paper
• Exploring Hippo YAP/TAZ Signaling: A Novel Avenue for Cardiovascular Disorders

  2025cites this paper
• GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients

  2024cites this paper
• Effects of Lipoproteins on Metabolic Health

  2024cites this paper
• An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus

  2023cites this paper
• Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions

  2023cites this paper
• Hypoglycemic Activity of Glycyrrhizic Acid and Some of its Derivatives in the Alloxan Diabetes Model in Rats

  2021cites this paper
• Obesity: Molecular Mechanisms, Epidemiology, Complications and Pharmacotherapy

  2021cites this paper
• Two methods for the preparation of sitagliptin phosphate via chemical resolution and asymmetric hydrogenation

  2021cites this paper
• Tackling type 2 diabetes-associated cardiovascular and renal comorbidities: a key challenge for drug development

  2020cites this paper
• Ameliorating Role of Lepidium sativum Seeds Extract on Cardiac Muscle Impairment in Diabetic Albino Rats

  2020cites this paper
• Fermented rooibos extract attenuates hyperglycemia-induced myocardial oxidative damage by improving mitochondrial energetics and intracellular antioxidant capacity

  2020cites this paper
• Treatment and Management of Hypertension by Targeting ACE Inhibitors: in silico Approach

  2019cites this paper
• An update on therapies for the treatment of diabetes-induced osteoporosis

  2019influential citation
• Lanosteryl triterpenes from Protorhus longifolia as a cardioprotective agent: a mini review

  2018cites this paper
• Diabetic cardiomyopathy: molecular mechanisms, detrimental effects of conventional treatment, and beneficial effects of natural therapy

  2018cites this paper
• Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies.

  2017cites this paper
• Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.

  2017cites this paper
• Protection of SAL B with H9C2 cells

  2016cites this paper
• Resveratrol Ameliorates Diabetes-Induced Cardiac Dysfunction Through AT1R-ERK/p38 MAPK Signaling Pathway

  2016cites this paper
• The effects of crocin, insulin and their co-administration on the heart function and pathology in streptozotocin-induced diabetic rats

  2016cites this paper
• Evaluating the Phase II drugs currently under investigation for diabetic neuropathy

  2015cites this paper
• Glucose Homeostasis and Cardiovascular Alterations in Diabetes.

  2015influential citation
• A new face of endocannabinoids in pharmacotherapy. Part II: role of endocannabinoids in inflammation-derived cardiovaascular diseases.

  2014cites this paper
• The multicomponent Hantzsch reaction: comprehensive mass spectrometry monitoring using charge-tagged reagents.

  2014cites this paper
• Influence of naringin on the myocardial ultrastructure and NF-B expression in rats with diabetic cardiomyopathy

  2013cites this paper
• Structural changes in the myocardium during diabetes-induced cardiomyopathy

  2013cites this paper
• Investigating the effect of aspalathus linearis as a cardio-protective therapy in isolated rat cardiomyocytes

  2013cites this paper
• α-Lipoic acid attenuates LPS-induced cardiac dysfunction through a PI3K/Akt-dependent mechanism.

  2013cites this paper
• A ropinirol és a rosiglitazon proarrhythmiás hatásának vizsgálata kutya kamrai szívizomsejteken

  2013cites this paper
• Asymmetric Synthesis of a Glucagon Receptor Antagonist via Friedel–Crafts Alkylation of Indole with Chiral α-Phenyl Benzyl Cation

  2012cites this paper
• Mitochondrial tolerance to drugs and toxic agents in ageing and disease.

  2011cites this paper
• Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

  2011cites this paper